Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.76 USD | +1.34% | -1.73% | +18.91% |
31/05 | Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test | MT |
31/05 | Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.91% | 206Cr | |
-3.17% | 821.51Cr | |
+6.11% | 571.74Cr | |
+31.98% | 567.18Cr | |
-10.03% | 411.13Cr | |
-59.94% | 268.39Cr | |
+11.23% | 267.87Cr | |
-5.14% | 237.39Cr | |
-7.56% | 180.32Cr | |
+3.07% | 159.57Cr |
- Stock Market
- Equities
- MYGN Stock
- News Myriad Genetics, Inc.
- Goldman Sachs Adjusts Myriad Genetics' Price Target to $31 From $28, Maintains Buy Rating